First-in-Human trial launches for Off-the-Shelf cell therapy against tough cancers
NCT ID NCT07366658
First seen Feb 01, 2026 · Last updated May 15, 2026 · Updated 18 times
Summary
This early-phase study tests a new cell therapy called NEUK203-13 in up to 9 people with advanced small cell lung cancer or neuroendocrine tumors that have stopped responding to standard treatments. The therapy uses specially engineered immune cells (CAR-NK) made from stem cells, which are given after a short chemotherapy course. The main goal is to check safety and find the right dose, while also looking for early signs that the treatment might shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital of CICAMS
Beijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.